education
Hosted by Scientific Education Support · education · EN
The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. Hosted on Acast. See acast.com/privacy for more information.
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
32%
Guest openness
Selective
Sign up to generate a grounded pitch for Lymphoma Hub.
Signup to Generate a PitchThe Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
Lymphoma Hub is hosted by Scientific Education Support. The show has published 58 episodes to date.
Recent episodes include "How do you see tandem CAR T-cell therapies fitting into the future treatment landscape for LBCL?" (22 October 2026, 6 minutes), "What is the current clinical evidence for tandem CAR T-cell therapies in R/R DLBCL?" (22 September 2026, 6 minutes), and "What is the rationale for the development of tandem CAR T-cell therapies?" (15 September 2026, 8 minutes).
Lymphoma Hub publishes roughly weekly, with episodes averaging 11 minutes across 58 episodes.
Booking probability for Lymphoma Hub is 32%, and the host is rated Selective on guests. Lymphoma Hub requires a Pod Score of 80 or higher. Lymphoma Hub's contact route on record: verified email.
The strongest fits for Lymphoma Hub are Health & Wellness Services. Lymphoma Hub has an education audience.
Scientific Education Support hosts Lymphoma Hub, an education podcast with 58 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Lymphoma Hub
The Lymphoma Hub was pleased to speak with Ulrich Jäger, Medical University of Vienna, AT. We asked, How do you see tandem CAR T-cell therapies fitting into the future treatment landscape for LBCL? In this interview...
The Lymphoma Hub was pleased to speak to Nirav Shah, Medical College of Wisconsin, Milwaukee, US. We asked, What is the current clinical evidence for tandem chimeric antigen receptor (CAR) T-cell therapies in...
The Lymphoma Hub was pleased to speak with Peter Borchmann, University Hospital Cologne, DE. We asked, What is the rationale for the development of tandem chimeric antigen receptor (CAR) T-cell therapies? Intended for...
On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee member Francesc Bosch...
Lymphoma Hub
On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Farrukh Awan, University of Texas Southwestern Medical...
On June 22, 2026, the Lymphoma Hub held a virtual symposium, titled Optimizing treatment for chronic lymphocytic leukemia with BTK inhibitors. During the symposium, Lymphoma Hub Steering Committee member Susan O’Brien...
The Lymphoma Hub was pleased to speak with Gloria Iacoboni, Vall d'Hebron University Hospital, Barcelona, ES. We asked, What are the key findings from the DALY 2-EU trial of zamtocabtagene autoleucel (zamto-cel) in...
Lymphoma Hub
Following the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Lymphoma Hub spoke with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are...
Lymphoma Hub
During the Lymphoma Hub Steering Committee Meeting on April 20, 2026, key opinion leaders met to discuss results from the long-term follow-up of the phase III SEQUOIA trial (NCT03336333) evaluating zanubrutinib in...
During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Stephen Schuster, University of Pennsylvania, Philadelphia, US. We asked, What are the key...
During the American Society of Clinical Oncology Annual Meeting, May 19 – June 2, 2026, Chicago, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount Sinai, New York...
During the 31st European Hematology Association (EHA) Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Dr. Talha Munir, Leeds Teaching Hospital, Leeds, UK. We asked, What are the most recent...
Lymphoma Hub
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine at Mount...
Lymphoma Hub
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition , December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Alexey...
Lymphoma Hub
The Lymphoma Hub was pleased to speak to Susan O’Brien, Chao Family Comprehensive Cancer Center, University of California, Irvine, US. We asked, What do the clinical data tell us about fixed-duration ibrutinib +...
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Lorenzo Falchi, Memorial Sloan Kettering Cancer Center, New...
Lymphoma Hub
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Haifaa Abdulhaq, University of California, San Francisco...
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Adelba Torres, Hospital Auxilio Mutuo, San Juan, PR. We...
During the Lymphoma Hub Steering Committee Meeting on October 6, 2025, key opinion leaders met to discuss the results from the phase III STARGLO trial (NCT04408638) of glofitamab (Glofit) + gemcitabine + oxaliplatin...
The Lymphoma Hub was pleased to speak to Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, what factors influence Bruton’s tyrosine kinase inhibitor (BTKi) + B-cell lymphoma 2 inhibitor...
Recent guests on Lymphoma Hub. Study who booked and why before you pitch.
former director of the Maine Center for Disease Control & Prevention, and former principal deputy director of the U.S. Centers for Disease Control and Prevention, Association of State and Territorial Health Officials
researcher, Dana-Farber Cancer Institute
director of the Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai
professor, Department of Lymphoma and Myeloma, Columbia Student Investment Management Association
PitchCentric classifies Lymphoma Hub under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Multiple Myeloma Hub
AML Hub
MPN Hub
PeerVoice Oncology & Haematology Audio
Acute Lymphoblastic Leukemia CancerCare Connect Education Workshops
Chronic Lymphocytic Leukemia CancerCare Connect Education Workshops
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ